Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA
Health and Human Services Department; Food and Drug Administration · 2011
Read Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-15691.txt.
Description
Notice published in the Federal Register on 2011-06-23 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 36928-36929] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-15691] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2007-E-0226] Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA AGENCY: Food and Drug Administration, HHS.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 7 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Determination of Regulatory Review Period for Purposes of Patent Extension; BROVANA
Citation: us:fr:2011-15691
Creator: Health and Human Services Department; Food and Drug Administration
Year: 2011
Source-URL: https://www.federalregister.gov/documents/2011/06/23/2011-15691/determination-of-regulatory-review-period-for-purposes-of-patent-extension-brovana
Context: Notice published in the Federal Register on 2011-06-23 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo).
[Pages 36928-36929]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-15691]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-E-0226]
Determination of Regulatory Review Period for Purposes of Patent
Extension; BROVANA
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for BROVANA and is publishing this notice of
that determination as required by law. FDA has made the determination
because of the submission of an application to the Director of Patents
and Trademarks, Department of Commerce, for the extension of a patent
which claims that human drug product.
ADDRESSES: Submit electronic comments to http://www.regulations.gov.
Submit written petitions along with three copies and written comments
to the Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Beverly Friedman, Office of Regulatory
Policy, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
51, rm. 6222, Silver Spring, MD 20993-0002, 301-796-3602.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Director of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted as well as any time that may have occurred before the patent
was issued), FDA's determination of the length of a regulatory review
period for a human drug product will include all of the testing phase
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product BROVANA
(arformoterol tartrate). BROVANA is indicated for the long term, twice
daily (morning and evening) maintenance treatment of
bronchoconstriction in patients with chronic obstructive pulmonary
disease, including chronic bronchitis and emphysema. Subsequent to this
approval, the Patent and Trademark Office received a patent term
restoration application for BROVANA (U.S. Patent No. 6,589,508) from
Sepracor Inc. (now Sunovion Pharmaceuticals, Inc.), and the Patent and
Trademark Office requested FDA's assistance in determining this
patent's eligibility for patent term restoration and that FDA determine
the product's regulatory review period. In a letter dated June 1, 2011,
FDA advised the Patent and Trademark Office that this human drug
product had undergone a regulatory review period and that the approval
of BROVANA represented the first permitted commercial marketing or use
of the product.
FDA has determined that the applicable regulatory review period for
BROVANA is 3,118 days. Of this time, 2,819 days occurred during the
testing phase of the regulatory review period, while 299 days occurred
during the approval phase. These periods of time were derived from the
following dates:
1. The date an exemption under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(i)) became
effective: March 26, 1998. FDA has verified the applicant's claim that
the date the investigational new drug application became effective was
on March 26, 1998.
2. The date the application was initially submitted with respect to
the human drug product under section 505(b) of the FD&C Act: December
12, 2005. The applicant claims December 8, 2005, as the date the new
drug application (NDA) for Brovana (NDA 21-912) was initially
submitted. However, FDA records indicate that NDA 21-912 was submitted
on December 12, 2005.
3. The date the application was approved: October 6, 2006. FDA has
verified the applicant's claim that NDA 21-912 was approved on October
6, 2006.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 745 days of
patent term extension.
Anyone with knowledge that any of the dates as published are
incorrect may submit to the Division of Dockets Management (see
ADDRESSES) either electronic or written comments and ask for a
redetermination by August 22, 2011. Furthermore, any interested person
may petition FDA for a determination regarding whether the applicant
for extension acted with due diligence during the regulatory review
period by December 20, 2011. To meet its burden, the petition must
contain sufficient facts to merit an FDA investigation. (See H. Rept.
857, part 1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should
be in the format specified in 21 CFR 10.30.
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) electronic or written comments and written petitions.
It is only necessary to send one set of comments. It is no longer
necessary to send three copies of mailed comments. However, if you
submit a written petition, you must submit three copies of the
petition. Identify comments with the docket number found in brackets in
the heading of this document.
Comments and petitions that have not been made publicly available
on
[[Page 36929]]
http://www.regulations.gov may be viewed in the Division of Dockets
Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: June 2, 2011.
Jane A. Axelrad,
Associate Director for Policy, Center for Drug Evaluation and Research.
[FR Doc. 2011-15691 Filed 6-22-11; 8:45 am]